Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Trial details
- Registry ID
- NCT06830044
- Phase
- Phase 3
The FDA approved Milsaperidone (VHX-896) on 20 Feb 2026.
Drug identity checked against registry records
Also recorded as VHX-896
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044 | Vanda Pharmaceuticals | Phase 3 | Recruiting | 2028-03Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-02-20Day | Milsaperidone | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA220358", "applicant_as_listed_by_fda": "VANDA PHARMS INC", "brand_names": ["BYSANTI"], "active_ingredients": ["MILSAPERIDONE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20260220", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |